Cell-permeable chemical inhibitors have become invaluable reagents for the study of cellular regulation. In the present paper, using protein kinase inhibitors as the example, a set of criteria are described that should be met before any investigation using such compounds should be accepted for publication.
INTRODUCTION
Nearly all of the orally active drugs that have been developed by the pharmaceutical industry bind to protein 'targets'. In most cases, these compounds are inhibitors that switch off the biological activity of the target, although drugs that are agonists for particular receptors or enzyme activators have also been developed. These drugs, together with a vast number of other molecules that did not make it all the way to the clinic, have also become invaluable reagents for studying the physiological roles of the protein targets with which they interact.
The use of cell-permeable chemical inhibitors to address protein function has great advantages compared with other technologies, because the effect on the target can be assessed within minutes in primary cells and tissues. In contrast, siRNA (small interfering RNA) technology or the use of cells from 'knockout' mice has the potential disadvantage that the target has been ablated for a day or more (siRNA 'knockdown') or since the start of embryonic development ('knockout' cells). The effects that are observed may therefore be indirect and result from long-term alterations in gene expression programmes, while compensation by related isoforms is another potential hazard of these technologies. However, the use of small cell-permeable chemical inhibitors also has its limitations, the most serious being the inherent lack of specificity of these compounds. Table 1 Suggested criteria for the publication of studies using protein kinase inhibitors in intact cells
Essential criteria
1. The specificity of the chemical inhibitor must be tested against a large panel of protein kinases (at least 50, but preferably 100 or more), either by the author or another laboratory. The availability of this information is needed to provide an indication as to whether the effects of a compound are likely to be specific. 2. The cellular effects of the chemical inhibitor should be observed with at least two structurally unrelated inhibitors of the protein kinase. 3. The cellular effects of the chemical inhibitor should be observed at a concentration similar to that which prevents the phosphorylation of an established physiological target of the protein kinase. 4. If analogues are available, their rank order of potency in mediating the cellular effect should follow their rank order of potency in inhibiting the phosphorylation of a physiological target of the protein kinase. 5. The cellular effect should not be elicited by closely related analogues of the chemical inhibitor that do not affect the activity of the protein kinase in vitro. 6. It is essential that other laboratories are able to confirm the results. Papers should not therefore be published unless the chemical structure of the inhibitor is made available.
Desirable criteria
1. The effects of the compound should not be observed in cells that express a drug-resistant mutant of the protein kinase (e.g. [4] [5] [6] ). 2. The cellular effects of the compound should not be observed in cells in which the expression of the protein kinase and closely related isoforms have been ablated.
Over the past 15 years I have been involved in exploiting cellpermeable chemical inhibitors of protein kinases to understand the functions of these enzymes. The specificity problem is particularly acute in this field because, with over 500 members, protein kinases are one of the largest families of proteins encoded by the human genome. Moreover, the ATP-binding sites of protein kinases, with which most chemical inhibitors interact, are quite conserved, so that the probability of inhibiting protein kinases other than the target of interest is high.
Over the past 10 years, protein kinases have become the pharmaceutical industry's most popular drug target, especially in the field of cancer. As a result, a plethora of protein kinase inhibitors have become available from commercial suppliers, and researchers are faced with a bewildering array of thousands of compounds from which to choose, each claiming to be a relatively 'specific' inhibitor of a particular kinase. To help to address this problem, we set up a large panel of protein kinases to assess the specificities of chemical inhibitors, which has expanded over the years to approx. 100 enzymes and has recently become the National Centre for Protein Kinase Profiling (http://www.kinasescreen.mrc.ac.uk). Several other commercial ventures to monitor the specificity of kinase inhibitors have been established over the last few years. The use of the panel mentioned above immediately revealed that most chemical inhibitors of protein kinases that are available commercially are so non-specific that conclusions drawn about the roles of particular protein kinases from the use of such compounds are almost bound to be erroneous. I thought that this information might be useful to the cell signalling community, but was taken aback by the deluge of emails that followed the publication of these papers [1] [2] [3] , which exceeded by far the reaction to any other paper I have published. The first paper has been cited 2240 times and was downloaded from the Biochemical Journal website 7600 times in 2004 alone. This is a reflection of the huge need for chemical inhibitors of protein kinases and the impact that they are now having on the study of cell signalling.
It is clearly essential to formulate a set of criteria that should be met before a compound can be said to exert its effects on cells by inhibiting a particular protein target. I have proposed the criteria for protein kinase inhibitors (Table 1) , but similar criteria can be applied to any compound that inhibits a particular protein target. It should be noted that non-specific inhibitors of protein kinases do have an important use, namely to exclude the involvement of a protein kinase in a particular cellular response. 
